Company / R&D per Share
Lineage Cell Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.08
FY2025
5-year range
$0.07 / $0.20
FY2021-FY2025
Trend
+12.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share returned to growth in FY2025 after 2 years of decline, reaching $0.08.
Based on SEC 10-K filings.
0.08 in FY2025 with a 5-year CAGR of -7.7%.
Declined from $0.09 to $0.08 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -26.2%
- 5-Year CAGR
- -7.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share increased 12.9% year-over-year.
- Peak r&d per share was recorded in FY2016.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.08 | +12.9% |
| FY2024 | $0.07 | -22.8% |
| FY2023 | $0.09 | -53.9% |
| FY2022 | $0.20 | +148.7% |
| FY2021 | $0.08 | -32.8% |
| FY2020 | $0.12 | -27.3% |
| FY2019 | $0.16 | -13.0% |
| FY2018 | $0.19 | -54.3% |
| FY2017 | $0.41 | -0.1% |
| FY2016 | $0.42 | +22.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026